Overview
VTGN market data
Price History
VTGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.20 – $5.14 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $9.8 · P/B 0.64 · P/S 7.75.
Company News
8-K filing — Vistagen Therapeutics, Inc. (VTGN)SEC EDGAR · Jul 31, 2026, 12:48 PM
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study MissBenzinga · Jun 30, 2026, 5:40 PM
Nasdaq Gains Over 300 Points; Chicago PMI Falls In JuneBenzinga · Jun 30, 2026, 4:10 PM
US Stocks Mixed; Home Prices Increase 1.1% In AprilBenzinga · Jun 30, 2026, 1:50 PM
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 30, 2026, 12:20 PM
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary EndpointBenzinga · Jun 30, 2026, 12:15 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga · Jun 30, 2026, 12:00 PM
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K EstimateBenzinga · Jun 15, 2026, 9:25 PM
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmBenzinga · Jun 1, 2026, 7:15 PM